Health
Moderna Plunges On Downgrade — Is Coronavirus Vaccine Maker Overvalued? – Investor’s Business Daily
Moderna stock fell Monday on a downgrade after an analyst suggested the coronavirus vaccine maker is overvalued. He now has a neutral rating on MRNA stock.
Moderna stock tumbled Monday after an analyst suggested the coronavirus vaccine maker is overvalued.
XJPMorgan Chase analyst Cory Kasimov acknowledged Moderna’s (MRNA) rapid development of a coronavirus vaccine is “impressive,” but he downgraded Moderna stock to a neutral rating following a 385% gain this year, as of Friday’s close.
Kasimov remains bullish on Moderna’s chance to be one of the first companies to cross the finish line with a coronavirus vaccine. The biotech company is using a me…
-
Business16 hours ago3 US dividend stocks that can boost an ASX retirement portfolio
-
Business13 hours agoTop brokers name 3 ASX shares to buy next week 16 November 2025
-
General23 hours agoEngland completes sole Ashes warm-up match with flurry of runs to Ollie Pope, Joe Root
-
General21 hours agoDemocratic Republic of Congo and M23 rebel group sign new roadmap to peace in Qatar